Lung Cancer Screening AI

V5med Inc.

Hsinchu, Taiwan

Founded in 2023, V5med is at the forefront of Medical Image AI innovation. Utilizing state-of-the-art AI technology, V5med has forged strategic partnerships with esteemed institutions, including Taipei Veterans General Hospital, National Taiwan University Hospital, and the Taiwan Lung Cancer Society. This collaboration has led to the development of V5 Lung AI , a groundbreaking computer-aided detection (CAD) system for lung cancer screening. V5 Lung AI transforms medical practice by enabling clinicians to detect nodules on low-dose CT (LDCT) images with unparalleled accuracy, thereby significantly reducing examination times . Beyond its efficiency, V5 Lung AI swiftly annotates nodules and provides essential details about their characteristics, such as diameter, volume, nodule type, and lung-RADS score. Remarkably, the system autonomously performs comparative analyses of nodule growth over time, delivering instantaneous assessments of volume doubling time (VDT). Additionally, V5 Lung AI produces detailed reports in accordance with ACR Lung-RADS and Fleischner guidelines following AI analysis. In addition to its pioneering work in lung cancer detection, V5med is committed to advancing technologies for quantifying pulmonary fibrosis, detecting COPD, assessing coronary artery calcification, and diagnosing osteoporosis. V5med's ultimate goal is to establish itself as a global leader in the realm of image AI solutions.